AbbVie Inc. $ABBV Shares Purchased by Verdence Capital Advisors LLC

Key Points

• Verdence Capital Advisors increased its AbbVie stake by 44.5% in the third quarter, owning 39,628 shares valued at approximately $10.4 million. Institutional investors collectively own 70.23% of ABBV.
• Analysts maintain a favorable outlook, with AbbVie receiving a consensus “Moderate Buy” rating and an average price target of $279.86; several firms recently raised their targets.
• AbbVie exceeded quarterly earnings and revenue estimates, while announcing a $1.73 quarterly dividend, equivalent to $6.92 annually and a 2.4% yield.

Verdence Capital Advisors LLC grew its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 44.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,628 shares of the company's stock after buying an additional 12,209 shares during the quarter. Verdence Capital Advisors LLC's holdings in AbbVie were worth $10,366,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ABBV. AGH Wealth Advisors LLC boosted its position in shares of AbbVie by 1.6% during the 3rd quarter. AGH Wealth Advisors LLC now owns 3,253 shares of the company's stock worth $851,000 after acquiring an additional 50 shares in the last quarter. Geneva Partners LLC bought a new position in AbbVie in the third quarter valued at approximately $3,124,000. Sunesis Advisors LLC bought a new position in AbbVie in the third quarter valued at approximately $2,396,000. Westover Capital Advisors LLC raised its position in AbbVie by 2.5% during the third quarter. Westover Capital Advisors LLC now owns 8,759 shares of the company's stock valued at $2,291,000 after purchasing an additional 210 shares in the last quarter. Finally, Peterson Wealth Services raised its position in AbbVie by 5.0% during the third quarter. Peterson Wealth Services now owns 15,285 shares of the company's stock valued at $3,998,000 after purchasing an additional 728 shares in the last quarter. Institutional investors own 70.23% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ABBV shares. Rothschild & Co Redburn upped their target price on AbbVie from $284.00 to $285.00 and gave the stock a "buy" rating in a research note on Tuesday, August 4th. Weiss Ratings upgraded AbbVie from a "buy (b-)" rating to a "buy (b)" rating in a research note on Thursday, October 8th. JPMorgan Chase & Co. lifted their price target on AbbVie from $285.00 to $300.00 and gave the company an "overweight" rating in a research note on Thursday, October 8th. Scotiabank boosted their price target on AbbVie from $280.00 to $320.00 and gave the stock an "outperform" rating in a report on Tuesday, October 6th. Finally, Oppenheimer upped their price objective on AbbVie from $244.00 to $258.00 and gave the stock a "neutral" rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, AbbVie presently has a consensus rating of "Moderate Buy" and an average price target of $279.86.

AbbVie Stock Performance

NYSE ABBV opened at $286.88 on Tuesday. The firm's fifty day moving average price is $266.18 and its two-hundred day moving average price is $235.62. The stock has a market cap of $506.85 billion, a PE ratio of 81.04, a PEG ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $291.40.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the business earned $2.97 earnings per share. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 13.93 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie's dividend payout ratio is presently 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved a subcutaneous induction regimen for AbbVie’s SKYRIZI in adults with moderately to severely active Crohn’s disease. The needle-based treatment option may improve convenience and support the drug’s continued growth across immunology indications. FDA approves subcutaneous SKYRIZI regimen
• Positive Sentiment: Goldman Sachs raised its price target for ABBV to $294, signaling continued confidence in the company’s outlook and providing a bullish valuation reference. Goldman Sachs raises AbbVie price target
• Positive Sentiment: Reports that Citadel has built an approximately $900 million position in AbbVie may boost sentiment by highlighting institutional interest in the company’s dividend and growth profile. Citadel AbbVie position
• Neutral Sentiment: Options markets imply roughly a 5% move around the October 30 earnings release, indicating that investors expect significant volatility as they assess results and forward guidance. AbbVie options and earnings volatility
• Neutral Sentiment: Coverage continues to describe AbbVie as an attractive, income-focused “Dividend King,” although its high earnings multiple makes future performance dependent on sustained earnings growth. AbbVie Dividend King coverage
• Negative Sentiment: Erste Group Bank reduced its EPS forecast and expressed a weak outlook for AbbVie’s fiscal 2026 earnings, creating a counterweight to the favorable product and institutional news. Erste Group lowers AbbVie EPS forecast

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company's stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by insiders.

AbbVie Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.